We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Atezolizumab and daratumumab

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02431208
Recruitment Status : Suspended
First Posted : April 30, 2015
Last Update Posted : December 6, 2017
Sponsor:
Information provided by (Responsible Party):

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : September 26, 2020
  Estimated Study Completion Date : September 26, 2020